Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. However patients do still relapse on ibrutinib, and the progressive disease is often quite a...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Hematol Oncol
Main Authors: Chen, Timothy L., Harrington, Bonnie, Truxall, Jean, Wasmuth, Ronni, Prouty, Alexander, Sloan, Shelby, Lehman, Amy M., Sampath, Deepa, Orlemans, Eric, Baiocchi, Robert A., Alinari, Lapo, Byrd, John C., Woyach, Jennifer A., Hertlein, Erin
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2021
Fag:
Letter to the Editor
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7905592/
https://ncbi.nlm.nih.gov/pubmed/33627156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01039-9
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker